Study of Trichloro(sulfanyl)ethyl Benzamides as TRPA1 Antagonists
Author Information
Author(s): Lana Klionsky, Rami Tamir, BaoXi Gao, Weiya Wang, David C Immke, Nobuko Nishimura, Narender R Gavva
Primary Institution: Amgen, Inc
Hypothesis
TRPA1 is a potential target for novel analgesic agents.
Conclusion
The study concludes that TCEB compounds are potent antagonists of human TRPA1 but exhibit differential pharmacology at rat TRPA1.
Supporting Evidence
- TCEB compounds were found to inhibit human TRPA1 activation by AITC and noxious cold.
- AMG9090 and AMG5445 acted as partial agonists at rat TRPA1.
- All four TCEB compounds showed high potency in inhibiting TRPA1 activation.
Takeaway
The researchers found that certain compounds can block a pain sensor in humans, which might help in creating new pain medications.
Methodology
The study used CHO cells expressing human and rat TRPA1 to screen a small molecule compound library for antagonists.
Potential Biases
All authors are employed by Amgen, Inc, which may introduce bias in the study.
Limitations
The study does not clarify the exact binding sites of the antagonists on the TRPA1 channel.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website